Immunome (IMNM) Other Accumulated Expenses (2020 - 2026)

Immunome has reported Other Accumulated Expenses for 7 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 162.4% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 162.4% YoY), and the FY2025 full-year result was $3.6 million, down 54.55% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.2 million, down from $3.6 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.0 million in Q4 2024, with the low at $61000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $991000.0 in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 96.39% — and 2023, when it soared 2900.0%.
• Immunome's Other Accumulated Expenses stood at $229000.0 in 2022, then surged by 219.65% to $732000.0 in 2023, then jumped by 989.89% to $8.0 million in 2024, then plunged by 54.55% to $3.6 million in 2025, then dropped by 12.44% to $3.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $3.2 million (Q1 2026), $3.6 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.